Table 1.
Baseline characteristics of STEMI patients
| Patient characteristics (n = 711) | |
|---|---|
| Age in years, median [IQR] | 58 [49, 68] |
| Male sex, No. (%) | 551 (77.5) |
| BMI, median [IQR] | 27.4 [24.8, 30.1] |
| BMI > 25 kg/m2, No. (%) | 525 (73.8) |
| BMI > 30 kg/m2, No. (%) | 182 (25.6) |
| Diabetes, No. (%) | 142 (20.0) |
| History of hypertension, No. (%) | 490 (68.9) |
| Dyslipidemia, No. (%) | 481 (67.7) |
| Ever smoker, No. (%) | 490 (68.9) |
| Family history of CAD, No. (%) | 246 (34.6) |
| Previous MI, No. (%) | 137 (19.3) |
| Culprit lesion, No. (%) | |
| LAD | 319 (44.9) |
| CX | 102 (14.3) |
| RCA | 262 (36.9) |
| Multiple | 10 (1.4) |
| Bypass | 18 (2.5) |
| CAD, No. (%) | |
| 1VD | 403 (56.7) |
| 2VD | 180 (25.3) |
| 3VD | 128 (18.0) |
| In-stent restenosis, No. (%) | 63 (8.9) |
| CRP, mg/dL (< 0.5), median [IQR] | 0.38 [0.18, 0.77] |
| Creatinine on admission, mg/dL (0.7–1.3), median [IQR] | 1.21 [1.05, 1.39] |
| Cholesterol, mg/dL (< 200), median [IQR] | 199.61 [170.66, 232.82] |
| LDL, mg/dL (< 130), median [IQR] | 113.13 [88.42, 140.15] |
| HDL, mg/dL (> 55), median [IQR] | 40.93 [35.14, 49.03] |
| Triglycerides, mg/dL (< 150), median [IQR] | 122.12 [81.42, 192.04] |
| CK-MB AUC, median [IQR] | 213.3 [95.5, 404.5] |
| STR, %, median [IQR] | 70.0 [38.4, 87.8] |
| Transthoracic echocardiography after STEMI | 365 (51.3) |
| Days after STEMI, median [IQR] | 3 [2, 4] |
| LVEF, %, median [IQR] | 49 [44, 56] |
| ESV, ml, median [IQR] | 49 [37, 66] |
| EDV, ml, median [IQR] | 98 [81, 120] |
| GLS, %, median [IQR] | − 14.1 [− 16.8, − 11.0] |
| Background medication prior to admission | |
| ACE inhibitors, No. (%) | 115 (16.2) |
| ARB, No. (%) | 72 (10.1) |
| Beta-blockers, No. (%) | 138 (19.4) |
| Statins, No. (%) | 140 (19.7) |
| ASA, No. (%) | 166 (23.3) |
Data are given as median [IQR] or percent of patients. Values in parentheses indicate reference values. Conversion factor for SI units for CRP 10; creatinine 76.25; cholesterol, LDL and HDL 0.0259; triglycerides 0.0113
ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, ASA acetylsalicylic acid, AUC area under the curve, BMI body mass index, CAD coronary artery disease, CK-MB creatine-phosphokinase isoform MB, CRP C-reactive protein, CX circumflex artery, EDV end-diastolic volume, ESV end-systolic volume, GLS global longitudinal strain, HDL high-density lipoprotein, IQR interquartile range, LAD left anterior descending artery, LDL low-density lipoprotein, LVEF left ventricular ejection fraction, MI myocardial infarction, MRA mineralocorticoid receptor antagonists, RCA right coronary artery, STR ST-segment resolution, SV stroke volume, VD vessel disease